Varisacumab Biosimilar – Anti-VEGFA mAb – Research Grade

Description of Varisacumab Biosimilar - Anti-VEGFA mAb - Research Grade

Varisacumab Biosimilar: A Potent Anti-VEGFA mAb for

Cancer Treatment Introduction

Varisacumab Biosimilar is a monoclonal antibody (mAb) that specifically targets vascular endothelial growth factor A (VEGFA), a key protein involved in angiogenesis and tumor growth. This biosimilar has been developed as a research grade therapeutic agent for the treatment of various types of cancer.

Structure of Varisacumab Biosimilar

Varisacumab Biosimilar is a recombinant humanized IgG1 mAb, with a molecular weight of approximately 150 kDa. It is produced by recombinant DNA technology in mammalian cell culture, ensuring high purity and stability. The antibody consists of two heavy chains and two light chains, connected by disulfide bonds. It has a unique amino acid sequence that specifically binds to VEGFA with high affinity and specificity.

Mechanism of Action

Varisacumab Biosimilar works by binding to VEGFA and preventing its interaction with its receptors, VEGFR1 and VEGFR2. This inhibits the downstream signaling pathway, leading to reduced angiogenesis and tumor growth. Additionally, the bound antibody can also induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against VEGFA-expressing tumor cells, further enhancing its anti-tumor activity.

Applications of Varisacumab Biosimilar

Varisacumab Biosimilar has shown promising results in pre-clinical and clinical studies as a potential therapeutic agent for various types of cancer. It has been evaluated in breast, lung, colorectal, and ovarian cancer models, and has demonstrated significant anti-tumor activity. In addition, this biosimilar has also shown potential as a combination therapy with other anti- cancer agents, such as chemotherapy and immune checkpoint inhibitors.

Advantages of Varisacumab Biosimilar

Compared to other anti-VEGFA mAbs, Varisacumab Biosimilar has several advantages. Firstly, its humanized structure reduces the risk of immune reactions and increases its half-life in the body. Secondly, its high specificity for VEGFA minimizes the potential for off-target effects. Thirdly, its potent anti-tumor activity has been demonstrated in various cancer models, making it a promising candidate for cancer treatment.

Conclusion

Varisacumab Biosimilar is a novel and promising therapeutic agent for the treatment of cancer. Its unique structure and mechanism of action make it a potent anti-VEGFA mAb, with high specificity and efficacy. Further research and clinical trials are needed to fully evaluate its potential as a cancer therapy, but it holds great promise for improving the treatment of various types of cancer.

Keywords: Varisacumab Biosimilar, monoclonal antibody, VEGFA, angiogenesis, tumor growth, cancer treatment, anti-tumor activity, humanized, specificity.

Varisacumab Biosimilar - Anti-VEGFA mAb binds to VEGFA / VEGF165, C-His, recombinant protein in indirect ELISA Assay

Immobilized VEGFA / VEGF165, C-His, recombinant protein (cat. No.PX-P5977) at 0.5µg/mL (100µL/well) can bind to Varisacumab Biosimilar - Anti-VEGFA mAb (cat. No.PX-TA1458) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450